药物洗脱支架在急性冠脉综合征中应用的思考

[11] Systemic inflammation in unstable angina is the result of myocardial necrosis. Cusack MR,Marber MS,Lambiase PD,et al. Journal of the American College of Cardiology . 2002

[12] Hypersensitivity cases associated with drug-eluting coronary stents:a reviewof available cases from the research on adverse drug events and reports(RADAR)project. Nebeker JR,Virmani R,Bennett CL,et al. Journal of the American College of Cardiology . 2006

[13] Multi-year follow-up of abciximab therapy in three randomized,placebo-controlled trials of percutaneous coronary revascularization. Topol EJ,Lincoff AM,Kereiakes DJ,et al. The American Journal of Medicine . 2002

[14] Multiple atherosclerotic plaque rupture in a-cute coronary syndrome:a three-vessel intravascular ultrasound study. Rioufol G,FinetG,Ginon IE,etal. Circulation . 2002

[15] Incidence,predictors,and outcome of thrombosis after successful implantation of drug-eluting stents. Iakovou I,Schmidt T,Bonizzoni E,et al. The Journal of The American Medical Association . 2005

[16] Pathologic assessment of the vulnera-ble human coronary plaque. Kolodgie FD,Virmani R,Burke AP,et al. Heart . 2004

[17] Short-and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with a-cute myocardial infarction. Lemos PA,Saia F,Hofma SH,et al. Journal of the American College of Cardiology . 2004

[18] Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction. Nebeker JR,Valgimigli M,Percoco G,et al. The Journal of The American Medical Association . 2005

[11] Systemic inflammation in unstable angina is the result of myocardial necrosis. Cusack MR,Marber MS,Lambiase PD,et al. Journal of the American College of Cardiology . 2002

[12] Hypersensitivity cases associated with drug-eluting coronary stents:a reviewof available cases from the research on adverse drug events and reports(RADAR)project. Nebeker JR,Virmani R,Bennett CL,et al. Journal of the American College of Cardiology . 2006

[13] Multi-year follow-up of abciximab therapy in three randomized,placebo-controlled trials of percutaneous coronary revascularization. Topol EJ,Lincoff AM,Kereiakes DJ,et al. The American Journal of Medicine . 2002

[14] Multiple atherosclerotic plaque rupture in a-cute coronary syndrome:a three-vessel intravascular ultrasound study. Rioufol G,FinetG,Ginon IE,etal. Circulation . 2002

[15] Incidence,predictors,and outcome of thrombosis after successful implantation of drug-eluting stents. Iakovou I,Schmidt T,Bonizzoni E,et al. The Journal of The American Medical Association . 2005

[16] Pathologic assessment of the vulnera-ble human coronary plaque. Kolodgie FD,Virmani R,Burke AP,et al. Heart . 2004

[17] Short-and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with a-cute myocardial infarction. Lemos PA,Saia F,Hofma SH,et al. Journal of the American College of Cardiology . 2004

[18] Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction. Nebeker JR,Valgimigli M,Percoco G,et al. The Journal of The American Medical Association . 2005